In yesterday’s Wall Street session, Esperion Therapeutics Inc. (NASDAQ:ESPR) shares traded at $2.68, up 2.29% from the previous session.
ESPR stock price is now 13.27% away from the 50-day moving average and 58.81% away from the 200-day moving average. The market capitalization of the company currently stands at $456.73M.
, while ‘Northland Capital’ rates the stock as ‘Market Perform’
In other news, Warren Eric, Chief Commercial Officer sold 742 shares of the company’s stock on Sep 20 ’23. The stock was sold for $924 at an average price of $1.25. Upon completion of the transaction, the Chief Commercial Officer now directly owns 68,318 shares in the company, valued at $0.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 18 ’23, Chief Commercial Officer Warren Eric sold 243 shares of the business’s stock. A total of $344 was realized by selling the stock at an average price of $1.41. This leaves the insider owning 69,060 shares of the company worth $0.19 million. A total of 1.10% of the company’s stock is owned by insiders.
During the past 12 months, Esperion Therapeutics Inc. has had a low of $0.70 and a high of $3.34. The fifty day moving average price for ESPR is $2.3682 and a two-hundred day moving average price translates $1.6948 for the stock.
The latest earnings results from Esperion Therapeutics Inc. (NASDAQ: ESPR) was released for Dec, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.5, missing analysts’ expectations of -$0.48 by -0.02. This compares to -$0.73 EPS in the same period last year. The company reported revenue of $32.25 million for the quarter, compared to $18.82 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 71.38 percent. For the current quarter, analysts expect ESPR to generate $84.51M in revenue.
